|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
4 Stamford Plaza, 9th Floor, Stamford, Connecticut 06902, US
|
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Cara Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
80%
|
The widely used Cara Therapeutics email format is {f}{last} (e.g. [email protected]) with 80% adoption across the company.
To contact Cara Therapeutics customer service number in your country click here to find.
Chris Posner is the CEO of Cara Therapeutics. To contact Chris Posner email at [email protected]. Or you may call 6105518706
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.